Log in

GeneNews Stock Price, Forecast & Analysis (TSE:GEN)

Today's Range N/A
50-Day Range
C$0.15
MA: C$0.14
C$0.15
52-Week Range N/A
Volume473,148 shs
Average Volume1.48 million shs
Market CapitalizationC$24.65 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
GeneNews Limited focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology, the Sentinel Principle, identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. GeneNews Limited was founded in 1998 and is headquartered in Richmond Hill, Canada.

Industry, Sector and Symbol

Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-905-7392030

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$234,592.00
Book ValueC($0.06) per share

Profitability

Miscellaneous

Employees15
Market CapC$24.65 million
Next Earnings DateN/A
OptionableOptionable

Receive GEN News and Ratings via Email

Sign-up to receive the latest news and ratings for GEN and its competitors with MarketBeat's FREE daily newsletter.


GeneNews (TSE:GEN) Frequently Asked Questions

What is GeneNews' stock symbol?

GeneNews trades on the Toronto Stock Exchange (TSX) under the ticker symbol "GEN."

Has GeneNews been receiving favorable news coverage?

Media headlines about GEN stock have trended very negative this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. GeneNews earned a news sentiment score of -3.2 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for GeneNews.

Who are some of GeneNews' key competitors?

What other stocks do shareholders of GeneNews own?

Who are GeneNews' key executives?

GeneNews' management team includes the folowing people:
  • Mr. James R. Howard-Tripp, Exec. Chairman & CEO
  • Ms. Joanna M. Halsey Esq., Gen. Counsel, Chief Compliance Officer & HR Director of IDL
  • Prof. Choong-Chin Liew Ph.D., Co-Founder
  • Mr. Warren Whitehead, Chief Accountant (Age 67)
  • Mr. David Suria, Sr. Scientist

How do I buy shares of GeneNews?

Shares of GEN and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

How big of a company is GeneNews?

GeneNews has a market capitalization of C$24.65 million and generates C$234,592.00 in revenue each year. GeneNews employs 15 workers across the globe.View Additional Information About GeneNews.

What is GeneNews' official website?

The official website for GeneNews is http://www.genenews.com/.

How can I contact GeneNews?

GeneNews' mailing address is 445 Apple Creek Blvd Unit 220, MARKHAM, ON L3R 9X7, Canada. The company can be reached via phone at +1-905-7392030.


MarketBeat Community Rating for GeneNews (TSE GEN)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  83 (Vote Outperform)
Underperform Votes:  89 (Vote Underperform)
Total Votes:  172
MarketBeat's community ratings are surveys of what our community members think about GeneNews and other stocks. Vote "Outperform" if you believe GEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel